Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GA-68 PSMA-11 PET To Evaluate Malignant Glioma Recurrence
NCT06444412Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Jan 2026
- Primary completion
- Jul 2028
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gallium ga-68 gozetotide in glioma, sponsored by Mayo Clinic. Primary endpoints: Adverse Events at 24 hours and Tolerability of PSMA positron emission tomography scan at 60 days. Started Jan 2026; status: recruiting.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06444412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06444412.